Filtered By:
Source: Skin and Allergy News
Condition: Arthritis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 70 results found since Jan 2013.
Ixekizumab improved psoriatic arthritis in patients who had not taken biologics
Two different doses of the humanized monoclonal antibody ixekizumab improved signs and symptoms of active psoriatic arthritis in a phase III manufacturer-sponsored trial of patients who had not taken a biologic drug before.
The agent selectively binds and neutralizes interleukin (IL)-17A, which...
Source: Skin and Allergy News - August 29, 2016 Category: Dermatology Source Type: news
Skin microbiome may differ in unique ways in psoriatic arthritis, psoriasis patients
MIAMI – As patients with psoriasis develop psoriatic arthritis, the abundance of particular genera in the skin microbiome decreases, according to a preliminary study characterizing cutaneous microbiota in these populations.
“The big overall message is there might be a decrease in microbiota...
Source: Skin and Allergy News - July 25, 2016 Category: Dermatology Source Type: news
Ultrasound’s role in detecting enthesitis in psoriatic arthritis remains debatable
MIAMI – Ultrasound-detected enthesitis was associated with both destructive and bone formation lesions on radiography of peripheral and axial joints in a study of 222 patients with psoriatic arthritis. But its lack of correlation to clinically detected enthesitis in this study and in others has...
Source: Skin and Allergy News - July 25, 2016 Category: Dermatology Source Type: news
Psoriatic arthritis patients face more endocrine comorbidities
MIAMI – Diabetes mellitus, hypothyroidism, Cushing’s disease, and osteoporosis occur more frequently in people with psoriatic arthritis than in controls, a large cohort study reveals. Prevalence of these endocrine conditions was greater in a group of 3,161 patients with psoriatic arthritis,...
Source: Skin and Allergy News - July 23, 2016 Category: Dermatology Source Type: news
Benefits, challenges emerge in evolution of rheumatology-dermatology clinics
MIAMI – Combined rheumatology-dermatology clinics to help people with psoriasis, psoriatic arthritis, and other relevant overlapping conditions continue to evolve, with evidence suggesting advantages and challenges for both patients and physicians.
Physicians like the improved communication and...
Source: Skin and Allergy News - July 21, 2016 Category: Dermatology Source Type: news
Psoriatic arthritis patients have elevated risk for coronary artery plaque
MIAMI – Patients with psoriatic arthritis had a higher prevalence and greater extent of coronary artery plaque in a pilot study comparison with healthy control patients that may point to increased risk independent of traditional cardiovascular risk factors.
In the study, coronary artery plaque as...
Source: Skin and Allergy News - July 21, 2016 Category: Dermatology Source Type: news
FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13 that the agency license a biosimilar Humira (adalimumab) that is made by Amgen and a biosimilar...
Source: Skin and Allergy News - July 13, 2016 Category: Dermatology Source Type: news
Obesity may attenuate anti-TNF response in psoriatic arthritis
LONDON – Patients with psoriatic arthritis appear less likely to achieve a good response to their first anti–tumor necrosis factor (anti-TNF) therapy if they are obese, according to data taken from two Nordic registries.
In a large observational cohort study, obese individuals with psoriatic...
Source: Skin and Allergy News - June 25, 2016 Category: Dermatology Source Type: news
TNF blocker safety may differ in RA and psoriasis patients
Rheumatoid arthritis patients on anti–tumor necrosis factor medications had approximately twice the rate of serious adverse events as did psoriasis patients on the same medications, based on data from a pair of prospective studies of about 4,000 adults.
The findings were published online in the...
Source: Skin and Allergy News - June 14, 2016 Category: Dermatology Source Type: news
Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
Tofacitinib, an oral Janus kinase (JAK)-1/3 inhibitor approved for treating rheumatoid arthritis, was beneficial in treating cutaneous dermatomyositis in three patients who had failed traditional therapies, according to a report published in JAMA Dermatology.
Dr. Drew J.B. Kurtzman of the...
Source: Skin and Allergy News - May 4, 2016 Category: Dermatology Source Type: news
How to beat apremilast-induced diarrhea
MAUI, HAWAII – If you’re going to prescribe apremilast for psoriasis or psoriatic arthritis – and more and more physicians are doing so because of the drug’s exceptional safety profile – you’d better get familiar with the oral phosphodiesterase-4 inhibitor’s gastrointestinal side effects, Dr....
Source: Skin and Allergy News - April 13, 2016 Category: Dermatology Source Type: news
Rosacea linked to several autoimmune diseases in women
Rosacea in women is linked with an increased risk for a wide variety of autoimmune disorders including type 1 diabetes, celiac disease, multiple sclerosis, and rheumatoid arthritis, according to a large population-based case-control study.
The finding expands the association of rosacea and...
Source: Skin and Allergy News - April 13, 2016 Category: Dermatology Source Type: news
Minimal disease activity criteria in PsA falls short
The minimal disease activity criteria used to identify low disease activity in psoriatic arthritis (PsA) may not be useful as a treatment target in patients with extended skin involvement, according to the results of a small study.
Minimal disease activity (MDA) for PsA is a composite measure...
Source: Skin and Allergy News - March 9, 2016 Category: Dermatology Source Type: news
Minimal disease activity criteria in PsA fall short
The minimal disease activity criteria used to identify low disease activity in psoriatic arthritis (PsA) may not be useful as a treatment target in patients with extended skin involvement, according to the results of a small study.
Minimal disease activity (MDA) for PsA is a composite measure...
Source: Skin and Allergy News - March 9, 2016 Category: Dermatology Source Type: news
Subclinical inflammation predicts progression from psoriasis to PsA
People with cutaneous psoriasis who have arthralgia and signs of subclinical inflammation on MRI are at an increased risk of progressing to psoriatic arthritis, according to findings from a cross-sectional, longitudinal study.
First author Dr. Francesca Faustini of the University of...
Source: Skin and Allergy News - February 29, 2016 Category: Dermatology Source Type: news
